MedTrace Logo

Timing and Duration of Acute Hepatitis C Treatment

NCT00241618 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2006-09-11

No results posted yet for this study

Summary

Spontaneous resolution of acute hepatitis C infection cannot be predicted and the majority of cases persist and become chronic. This randomized trial assesses the efficacy and safety of peginterferon alfa-2b. The investigators hypothesize that therapy strategies could prevent the development of chronic hepatitis.

Conditions

  • Hepatitis C

Interventions

DRUG

Pegylated interferon alpha 2

DRUG

Ribavirin

Sponsors & Collaborators

  • University Hospital Freiburg

    collaborator OTHER

  • Beth Israel Deaconess Medical Center

    collaborator OTHER

  • Alexander von Humboldt Association

    collaborator OTHER

  • Fulbright

    collaborator OTHER

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Tempus AI

    collaborator INDUSTRY

  • International Society for Infectious Diseases

    collaborator OTHER

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Alaa Ismail, M.D. · Ain Shams University

  • Sanaa M Kamal, M.D. · Ain Shams University

  • Nezam H Afdhal, M.D. · Harvard Medical School (HMS and HSDM)

  • Manal El Sayed, M.D. · ASU

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-01-31
Completion
2006-01-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00241618 on ClinicalTrials.gov